

# Special Issue

## Head and Neck Tumors, 4th Edition

### Message from the Guest Editors

Head and neck cancers dramatically impact patients' quality of life. Recently, remarkable progress has been made in reconstructive medical devices, and the use of stem cells has improved prosthetic support. However, there is still a need to improve early diagnosis and screening methodologies. This new Special Issue aims to present original, translational molecular, or clinical research and review articles that focus on the different aspects of head and neck pathology, including the following: identification of molecular markers of diagnosis, prognosis, and efficacy of therapy (e.g., liquid biopsy); new hypotheses of precision treatment; and the use of nanotechnologies and biomaterials to improve clinical outcome of the patients. Much interest will be devoted to the translational molecular mechanisms of recurrence and metastasis processes.

---

### Guest Editors

Dr. Silvia Di Agostino

Oncogenomic and Epigenetic Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Regina Elena National Cancer Institute, 00144 Rome, Italy

Prof. Dr. Jan B. Vermorken

1. Center for Oncological Research Antwerp, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium  
2. Department of Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Belgium

---

### Deadline for manuscript submissions

30 April 2026



# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9

CiteScore 6.8

Indexed in PubMed



[mdpi.com/si/220236](https://www.mdpi.com/si/220236)

*Biomedicines*

Editorial Office

MDPI, Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

---

[mdpi.com/journal/  
biomedicines](https://www.mdpi.com/journal/biomedicines)





# Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](http://mdpi.com/journal/biomedicines)

## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

